Wall Street closes at a record for the first time since end of January
TAIPEI - YD Bio Limited (NASDAQ:YDES) has signed a non-binding Memorandum of Understanding to merge with EG BioMed, a company specializing in DNA methylation-based cancer diagnostics and AI-driven biomarker analytics, the company announced Tuesday. YD Bio, currently valued at $891.66 million in market capitalization, has seen its stock price fall significantly over the last three months according to InvestingPro data.
The proposed merger aims to create an integrated oncology platform spanning early cancer detection, clinical data generation, and AI-enabled drug discovery. The transaction is anticipated to close in 2026, subject to regulatory approvals and finalization of definitive agreements.
EG BioMed’s technology focuses on DNA methylation profiling, an epigenetic approach for detecting cancer-associated molecular changes. Its platform has shown clinical performance in early cancer detection, including pancreatic cancer.
According to the company, EG BioMed’s cancer detection platform has been approved for clinical adoption at three affiliated medical centers of Taipei Medical University, where it is being integrated into hospital workflows to assist clinicians in monitoring treatment response and disease progression.
"It is now being integrated into hospital workflows to assist clinicians in monitoring treatment response, disease progression, and recurrence," said Dr. Ethan Shen, Chairman and CEO of YD Bio.
The companies believe the merger could accelerate YD Bio’s transition from a technology-focused company to a platform-based organization anchored in clinically validated molecular data. Despite this strategic move, InvestingPro data shows YD Bio currently trades at a P/E ratio of -9.61 and suffers from weak gross profit margins, though the company maintains a strong balance sheet with zero debt.
YD Bio cautioned that there is no assurance the parties will enter into definitive agreements or consummate the merger on the terms contemplated. Any integration benefits, including potential revenue growth, platform expansion, or cost synergies, remain subject to numerous assumptions and risks.
Based on the press release statement, the proposed merger represents a strategic move in YD Bio’s efforts to expand its capabilities in cancer diagnostics and treatment.
In other recent news, YD Bio Limited has made significant strides in its technology platforms and regulatory achievements. The company reported completing Chemistry, Manufacturing, and Controls development for its Limbal Stem Cell platform and stem cell-derived exosome products, and has filed Drug Master Files with the U.S. Food and Drug Administration. Additionally, YD Bio has expanded its OkaiDx blood-based testing platform to include pancreatic and colorectal cancer detection services, now available across 44 U.S. states through EG BioMed’s certified laboratory. The company also announced plans to establish a new operations center in California to further advance its cancer detection and ophthalmologic technologies, although the specific location has not been finalized.
In regulatory news, YD Bio’s partner, 3D Global Biotech, received FDA 510(k) clearance for Exovisse Contact Lenses, classifying them as a Class II medical device, allowing legal marketing in the United States. Moreover, its Exovisse Artificial Tears have been developed in compliance with FDA guidelines, enabling nationwide over-the-counter distribution. These developments mark YD Bio’s entry into the American ophthalmology market. These recent advancements highlight YD Bio’s ongoing efforts to expand its technological capabilities and market presence in the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.